FDA Warning Letter Cites Quality Control Issues At Abbott Diabetes Care
This article was originally published in The Gray Sheet
Executive Summary
Abbott's Diabetes Care division did not follow internal protocols for quality control testing of its FreeStyle blood glucose monitoring systems and FreeStyle Navigator continuousglucose monitoring systems, FDA alleged in a July 2 warning letter to the firm